LACTOLOGY FOUNDATION

A07XA Other Antidiarrheals: Toxicological and Lactological Monograph

ATC Class and General Pharmacology

A07XA, Other antidiarrheals, is a fifth-level pharmacological subgroup within A07X, Other antidiarrheals, under the broader ATC category A07, Antidiarrheals, intestinal anti-inflammatory/anti-infective agents. It includes pharmacologically heterogeneous oral treatments used for symptomatic management of diarrhoea when they do not fit more specific ATC antidiarrhoeal categories. The ATC/DDD Index specifically assigns albumin tannate, ceratonia/carob preparations, calcium compounds, racecadotril, crofelemer, and albumin-tannate combinations to A07XA; combinations with pectin and magnesium peroxide are also classified in this subgroup.atcddd.fhi+1

A07XA is not a mechanistically uniform drug class. Its members include substances with local astringent actions, preparations that can affect stool consistency or intestinal luminal conditions, and targeted antisecretory agents. Consequently, the pharmacological effects of A07XA medicines may arise through different mechanisms:

• Reduction of intestinal fluid and electrolyte secretion.
• Modification of epithelial ion transport and secretory activity.
• Local mucosal astringency or protection.
• Reduction of stool water content and improvement of stool consistency.
• Supportive symptomatic control without a primary antimicrobial effect.
• Possible interaction with intestinal contents, including co-administered drugs, in certain formulations.

Some A07XA agents act primarily in the gastrointestinal lumen and have limited systemic absorption. Others, particularly medicines with defined antisecretory pharmacology, may undergo measurable systemic absorption before acting on intestinal epithelial mechanisms. Therefore, class membership alone does not permit extrapolation of efficacy, systemic exposure, toxicity, placental transfer, breast-milk passage, or infant safety from one agent to another.

These agents are intended for symptomatic management and should not replace identification of the underlying cause of diarrhoea. Acute diarrhoea may result from infection, food-related illness, drug exposure, inflammatory bowel disease, endocrine disorders, malabsorption, or treatment-related secretory diarrhoea. Pharmacological symptom control is secondary to adequate fluid and electrolyte replacement, particularly in patients with clinically significant fluid loss.

Toxicological Profile

The toxicological profile of A07XA is variable and depends on the specific active substance, pharmaceutical formulation, dose, duration of use, gastrointestinal integrity, renal and hepatic function, concurrent medication, and patient susceptibility. Most products are administered orally and are commonly used for short periods; nevertheless, short duration does not eliminate the need for toxicological evaluation.

Class-level adverse effects may include constipation, abdominal pain, bloating, nausea, vomiting, altered stool pattern, and reduced gastrointestinal tolerance. Symptom reduction can also create a clinical risk if it delays assessment of severe, persistent, invasive, or inflammatory diarrhoeal disease.

Important toxicological considerations include:

• Dehydration and electrolyte disturbance: Antidiarrhoeal therapy does not correct fluid loss. Inadequate oral rehydration can lead to worsening dehydration, hypotension, weakness, renal dysfunction, or clinically relevant electrolyte abnormalities.
• Underlying disease masking: Persistent diarrhoea, fever, bloody stool, severe abdominal pain, systemic toxicity, or suspected infectious colitis require medical assessment rather than prolonged self-treatment.
• Drug absorption interactions: Locally acting or astringent substances may alter intestinal drug absorption through adsorption, binding, delayed dissolution, or mucosal effects. Temporal separation from concomitant oral medicines may be prudent where clinically relevant.
• Hypersensitivity: Allergic or idiosyncratic reactions are possible, particularly with protein-containing, plant-derived, or complex formulations.
• Mineral-related effects: Preparations containing calcium or other mineral components may have product-specific systemic and gastrointestinal effects, especially at high doses, with prolonged administration, or in renal impairment.
• Composition variability: Non-standardised botanical products and combination preparations may contain variable quantities of bioactive constituents and excipients, which increases uncertainty regarding toxicity and interaction potential.

The toxicological interpretation of a substance that remains mainly within the intestinal lumen differs fundamentally from that of an agent with measurable systemic absorption. For the latter, evaluation should include systemic adverse effects, metabolic pathways, active metabolites, organ dysfunction, drug–drug interactions, and risk associated with repeated dosing.

Lactation Pharmacology and Infant Exposure

Lactation assessment for A07XA should be performed at the level of the individual medicine, rather than by applying a single safety label to the entire subgroup. The determinants of infant exposure during breastfeeding are maternal plasma concentration, molecular properties, protein binding, lipid solubility, ionisation, volume of distribution, elimination half-life, active metabolites, and the infant’s capacity to absorb and eliminate the substance.

For a locally acting, minimally absorbed A07XA preparation, maternal systemic concentrations are expected to be very low. As transfer into breast milk generally requires maternal systemic availability, clinically important passage into milk would be unlikely in this setting. Furthermore, if the medicine has poor oral bioavailability, any trace quantity ingested through milk may be poorly absorbed by the infant. This is a pharmacokinetic rationale for low expected infant exposure, but it should not be considered equivalent to direct evidence of lactation safety.

In contrast, an A07XA medicine with systemic absorption or a defined molecular target may have a different lactation profile. The absence of a high theoretical exposure does not exclude milk transfer, metabolite transfer, or pharmacological effects in a vulnerable infant. Direct measurements of drug or metabolite concentrations in human milk, infant plasma concentrations, and documented infant outcomes remain the strongest evidence for lactation safety.

Factors that can increase uncertainty include:

• Maternal high-dose, repeated, or long-term therapy.
• Severe maternal gastrointestinal inflammation or mucosal damage that may increase absorption of an otherwise poorly absorbed substance.
• Use of combination formulations with poorly characterised components.
• Prematurity, neonatal age, low body weight, impaired renal function, hepatic disease, or gastrointestinal disease in the infant.
• Co-exposure of the infant to medicines that may have overlapping gastrointestinal or metabolic effects.

During maternal therapy, relevant infant monitoring parameters include feeding behaviour, vomiting, stool frequency and consistency, constipation, abdominal distension, irritability, unusual somnolence, hydration status, and weight gain. These observations are precautionary and nonspecific; they should be interpreted in the clinical context, because acute infant gastrointestinal symptoms often have causes unrelated to drug exposure through milk.

Lactological Safety Assessment and Clinical Recommendations

At class level, A07XA should be categorised as a heterogeneous group with generally low predicted exposure for locally acting products, but with substance-specific uncertainty. Continued breastfeeding is usually reasonable when a breastfeeding patient requires short-term treatment with a well-characterised, minimally systemically absorbed A07XA medicine, provided the maternal condition is uncomplicated and the infant is clinically well.

The following clinical principles are recommended:

1. Treat maternal dehydration first. Oral rehydration, adequate dietary intake, and correction of electrolyte losses are fundamental. Antidiarrhoeal medicines provide symptomatic support and do not substitute for rehydration.
2. Clarify the indication. Determine whether maternal diarrhoea is uncomplicated and self-limited or associated with red flags such as fever, blood in stool, severe pain, systemic illness, recent antimicrobial exposure, or persistent symptoms.
3. Prefer an individual agent with a favourable pharmacokinetic profile. When treatment is necessary, select a single-ingredient, standardised product with low systemic bioavailability, minimal interaction potential, and an appropriate evidence base for the intended use.
4. Avoid unnecessary exposure. Use the lowest effective dose for the shortest clinically appropriate duration. Reassess rather than extending treatment when symptoms persist.
5. Avoid poorly defined formulations when possible. Complex herbal mixtures, variable botanical preparations, and multi-component products may create avoidable uncertainty about maternal toxicity, milk transfer, and infant exposure.
6. Continue breastfeeding when clinically appropriate. Maternal acute diarrhoea alone is not generally an indication to interrupt breastfeeding. Attention to hand hygiene and food safety is important when infectious gastroenteritis is possible.
7. Use enhanced caution in vulnerable infants. Seek specialised lactation-pharmacology or paediatric advice when the infant is premature, neonatal, medically unstable, has renal/hepatic impairment, or when maternal treatment is prolonged or involves a systemically absorbed A07XA medicine.
8. Monitor and escalate when required. Medical assessment is indicated for maternal signs of dehydration, persistent or severe diarrhoea, bloody stools, fever, abdominal pain, reduced urine output, or inability to maintain oral intake. Infant clinical review is indicated for poor feeding, lethargy, fever, vomiting, reduced urine output, persistent diarrhoea, constipation with distress, or poor weight gain.

In conclusion, A07XA is a classification subgroup rather than a unified lactation safety category. A short course of a standardised, minimally absorbed local product will often present a low theoretical risk to the breastfed infant; however, definitive safety categorisation must remain agent-specific and should be based on the active substance, formulation, maternal dose, duration, systemic exposure, available human lactation data, and infant clinical vulnerability.